Immatics Total Current Liabilities vs Selling General Administrative Analysis

IMTXW Stock

USD 0.34 0.08 19.05%

Immatics Biotechnologies financial indicator trend analysis is infinitely more than just investigating Immatics Biotechnologies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immatics Biotechnologies is a good investment. Please check the relationship between Immatics Biotechnologies Total Current Liabilities and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Total Current Liabilities vs Selling General Administrative

Total Current Liabilities vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immatics Biotechnologies Total Current Liabilities account and Selling General Administrative. At this time, the significance of the direction appears to have strong relationship.

The correlation between Immatics Biotechnologies' Total Current Liabilities and Selling General Administrative is 0.73. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of immatics biotechnologies GmbH, assuming nothing else is changed. The correlation between historical values of Immatics Biotechnologies' Total Current Liabilities and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of immatics biotechnologies GmbH are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Total Current Liabilities i.e., Immatics Biotechnologies' Total Current Liabilities and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Immatics Biotechnologies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of immatics biotechnologies GmbH are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Selling General Administrative

Most indicators from Immatics Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immatics Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in immatics biotechnologies GmbH. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Sales General And Administrative To Revenue is likely to climb to 1.03 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	5.7M	9.4M	13.8M	14.5M
Net Interest Income	3.9M	1.1M	13.0M	13.7M

Interest Income Net Interest Income

Immatics Biotechnologies fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Common Stock Shares Outstanding		0.62	0.61	0.58	0.85	0.47	0.7	0.9	-0.25	-0.41	0.8	0.24	0.75	0.71	0.59	0.31	0.71	0.41	0.61	-0.86	0.67	0.46	0.88	0.47	0.66	0.59
Total Assets	0.62		0.94	0.8	0.9	0.98	0.86	0.73	-0.8	-0.84	0.33	0.86	0.94	0.69	1.0	0.33	0.95	0.13	0.94	-0.46	0.93	0.93	0.78	0.98	0.78	1.0
Short Long Term Debt Total	0.61	0.94		0.94	0.91	0.95	0.84	0.6	-0.72	-0.92	0.17	0.78	0.92	0.61	0.94	0.01	0.91	-0.16	1.0	-0.63	0.92	0.97	0.65	0.95	0.69	0.94
Other Current Liab	0.58	0.8	0.94		0.88	0.81	0.8	0.51	-0.64	-0.92	0.1	0.69	0.86	0.36	0.78	-0.21	0.72	-0.34	0.94	-0.69	0.82	0.92	0.54	0.81	0.63	0.78
Total Current Liabilities	0.85	0.9	0.91	0.88		0.82	0.89	0.86	-0.64	-0.79	0.54	0.69	0.98	0.62	0.87	0.24	0.87	0.15	0.91	-0.73	0.89	0.84	0.88	0.82	0.8	0.88
Total Stockholder Equity	0.47	0.98	0.95	0.81	0.82		0.81	0.58	-0.81	-0.88	0.14	0.88	0.88	0.62	0.99	0.19	0.92	-0.04	0.95	-0.39	0.9	0.96	0.64	1.0	0.7	0.98
Property Plant And Equipment Net	0.7	0.86	0.84	0.8	0.89	0.81		0.73	-0.85	-0.88	0.39	0.79	0.89	0.49	0.84	0.26	0.77	0.13	0.84	-0.6	0.97	0.84	0.77	0.81	0.96	0.85
Current Deferred Revenue	0.9	0.73	0.6	0.51	0.86	0.58	0.73		-0.45	-0.43	0.88	0.48	0.83	0.67	0.7	0.64	0.74	0.63	0.6	-0.57	0.69	0.51	1.0	0.58	0.77	0.71
Net Debt	-0.25	-0.8	-0.72	-0.64	-0.64	-0.81	-0.85	-0.45		0.87	-0.06	-0.97	-0.74	-0.21	-0.8	-0.31	-0.6	-0.02	-0.72	0.11	-0.84	-0.84	-0.52	-0.81	-0.84	-0.8
Retained Earnings	-0.41	-0.84	-0.92	-0.92	-0.79	-0.88	-0.88	-0.43	0.87		0.03	-0.87	-0.83	-0.31	-0.84	0.08	-0.71	0.3	-0.92	0.47	-0.91	-0.96	-0.49	-0.88	-0.76	-0.84
Accounts Payable	0.8	0.33	0.17	0.1	0.54	0.14	0.39	0.88	-0.06	0.03		0.07	0.48	0.51	0.3	0.72	0.4	0.83	0.17	-0.41	0.3	0.05	0.84	0.14	0.5	0.31
Cash	0.24	0.86	0.78	0.69	0.69	0.88	0.79	0.48	-0.97	-0.87	0.07		0.81	0.25	0.86	0.31	0.66	0.0	0.78	-0.09	0.8	0.89	0.55	0.88	0.76	0.86
Non Current Assets Total	0.75	0.94	0.92	0.86	0.98	0.88	0.89	0.83	-0.74	-0.83	0.48	0.81		0.58	0.93	0.31	0.87	0.16	0.92	-0.58	0.9	0.89	0.87	0.88	0.82	0.93
Non Currrent Assets Other	0.71	0.69	0.61	0.36	0.62	0.62	0.49	0.67	-0.21	-0.31	0.51	0.25	0.58		0.7	0.36	0.87	0.39	0.61	-0.57	0.62	0.46	0.69	0.62	0.42	0.7
Cash And Short Term Investments	0.59	1.0	0.94	0.78	0.87	0.99	0.84	0.7	-0.8	-0.84	0.3	0.86	0.93	0.7		0.33	0.95	0.12	0.94	-0.43	0.92	0.93	0.76	0.99	0.76	1.0
Net Receivables	0.31	0.33	0.01	-0.21	0.24	0.19	0.26	0.64	-0.31	0.08	0.72	0.31	0.31	0.36	0.33		0.29	0.93	0.01	0.22	0.21	0.02	0.65	0.19	0.46	0.33
Short Term Investments	0.71	0.95	0.91	0.72	0.87	0.92	0.77	0.74	-0.6	-0.71	0.4	0.66	0.87	0.87	0.95	0.29		0.18	0.91	-0.58	0.87	0.83	0.78	0.92	0.66	0.95
Non Current Liabilities Total	0.41	0.13	-0.16	-0.34	0.15	-0.04	0.13	0.63	-0.02	0.3	0.83	0.0	0.16	0.39	0.12	0.93	0.18		-0.16	0.08	0.07	-0.21	0.61	-0.04	0.33	0.13
Capital Lease Obligations	0.61	0.94	1.0	0.94	0.91	0.95	0.84	0.6	-0.72	-0.92	0.17	0.78	0.92	0.61	0.94	0.01	0.91	-0.16		-0.63	0.92	0.97	0.65	0.95	0.69	0.94
Inventory	-0.86	-0.46	-0.63	-0.69	-0.73	-0.39	-0.6	-0.57	0.11	0.47	-0.41	-0.09	-0.58	-0.57	-0.43	0.22	-0.58	0.08	-0.63		-0.6	-0.46	-0.54	-0.39	-0.46	-0.44
Other Current Assets	0.67	0.93	0.92	0.82	0.89	0.9	0.97	0.69	-0.84	-0.91	0.3	0.8	0.9	0.62	0.92	0.21	0.87	0.07	0.92	-0.6		0.9	0.74	0.9	0.9	0.92
Other Stockholder Equity	0.46	0.93	0.97	0.92	0.84	0.96	0.84	0.51	-0.84	-0.96	0.05	0.89	0.89	0.46	0.93	0.02	0.83	-0.21	0.97	-0.46	0.9		0.57	0.96	0.71	0.93
Total Liab	0.88	0.78	0.65	0.54	0.88	0.64	0.77	1.0	-0.52	-0.49	0.84	0.55	0.87	0.69	0.76	0.65	0.78	0.61	0.65	-0.54	0.74	0.57		0.64	0.81	0.77
Net Invested Capital	0.47	0.98	0.95	0.81	0.82	1.0	0.81	0.58	-0.81	-0.88	0.14	0.88	0.88	0.62	0.99	0.19	0.92	-0.04	0.95	-0.39	0.9	0.96	0.64		0.7	0.98
Property Plant And Equipment Gross	0.66	0.78	0.69	0.63	0.8	0.7	0.96	0.77	-0.84	-0.76	0.5	0.76	0.82	0.42	0.76	0.46	0.66	0.33	0.69	-0.46	0.9	0.71	0.81	0.7		0.76
Total Current Assets	0.59	1.0	0.94	0.78	0.88	0.98	0.85	0.71	-0.8	-0.84	0.31	0.86	0.93	0.7	1.0	0.33	0.95	0.13	0.94	-0.44	0.92	0.93	0.77	0.98	0.76

Click cells to compare fundamentals

Immatics Biotechnologies Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immatics Total Current Liabilities vs Selling General Administrative Analysis

Total Current Liabilities vs Selling General Administrative

Total Current Liabilities vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Selling General Administrative

Immatics Biotechnologies fundamental ratios Correlations

Immatics Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Immatics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Current Deferred Revenue
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Capital Lease Obligations	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Other Current Liab
Retained Earnings	- 0.92	Short Long Term Debt Total
Other Current Assets	- 0.91	Retained Earnings